Abstract
Recombinant human erythropoietin (rHuEpo) is an established, effective treatment for the anemia of chronic renal failure. Recent reports also suggest it may be efficacious in the anemias of drug toxicity, rheumatoid arthritis, and multiple myeloma without renal failure. We describe the positive response to rHuEpo in an end-state renal disease patient with active multiple myeloma and ongoing chemotherapy. Before rHuEpo therapy, the patient was transfusion dependent, but after rHuEpo was initiated, transfusions were not required. Multiple myeloma with renal failure does not preclude a response to rHuEpo. Further trials of rHuEpo in the treatment of multiple myeloma with and without renal failure are warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 145-147 |
Number of pages | 3 |
Journal | Clinical Nephrology |
Volume | 37 |
Issue number | 3 |
State | Published - 1992 |
Externally published | Yes |
Keywords
- Dialysis
- Erythropoietin
- Multiple myeloma
ASJC Scopus subject areas
- Nephrology